Radiopharmaceuticals Market Report: Size, Share & Trends 2026–2035

The Radiopharmaceuticals Market encompasses diagnostic tracers used in SPECT and PET imaging, therapeutic radioligands and alpha-emitters, and the isotope generators and kits that feed them, spanning eight commercial isotopes from Technetium-99m to Radium-223.

The value chain runs in three tiers. Foundational providers such as Eckert & Ziegler, SHINE Technologies and NorthStar Medical Radioisotopes produce the isotopes and generators. Specialist developers — Novartis, Lantheus, Bayer and Telix Pharmaceuticals — own the approved agents and pipelines. Application-layer specialists including Cardinal Health, Siemens Healthineers and Jubilant Pharmova compound, dispense and deliver patient doses through radiopharmacy networks, often within hours of production.

For procurement and investment teams, value is concentrating in therapeutic doses, PET tracers and secured isotope offtake rather than in legacy SPECT volume. This report's segmentation framework covers 4 dimensions and 35+ countries across six regions, so buyers can test where supply contracts, site build-outs and licensing deals will earn the highest return over the forecast horizon.

According to GLOBOCAN 2022 (International Agency for Research on Cancer), as reported by the World Cancer Research Fund, 2022, 1,467,854 new prostate cancer cases were diagnosed worldwide in 2022, making it the second most common cancer in men — the core patient pool for PSMA-PET imaging and PSMA-targeted radioligand therapy.

AI is changing how radiopharmaceutical patients are selected and dosed. In January 2026, GE HealthCare received FDA 510(k) clearance for MIM LesionID Pro, which automatically segments whole-body tumour burden on PSMA PET/CT and SPECT/CT scans to support therapy candidacy and track response across treatment cycles. Work that once took a nuclear medicine physician hours of manual contouring now runs in minutes, and it produces the standardised lesion counts that dosimetry and payer reviews increasingly expect.

For hospitals, the payoff is throughput: AI-assisted quantification lets a fixed number of physicians handle more theranostic patients, which matters when dose demand may rise sixfold. In Korea, DuChemBio is commercialising software that predicts late-phase PET images from early scans. Expect AI dosimetry to become a standard part of radioligand therapy planning before 2030.

Novartis' two radioligand brands, Pluvicto and Lutathera, earned a combined USD 2,810 Mn in 2025 — a single company's therapy revenue equal to roughly 30% of the whole category. Even so, diagnostic radiopharmaceuticals remain the dominant product type at 57.0% of 2025 revenue (USD 5,272.5 Mn), because every SPECT bone, cardiac and thyroid scan and every PET staging study consumes a tracer dose, and those procedures run in the tens of millions each year. Therapeutic radiopharmaceuticals hold 43.0% (USD 3,976.1 Mn) but are compounding at a 15.3% two-year CAGR versus 7.6% for diagnostics. The gap comes from price per dose: a Lutetium-177 therapy cycle bills at many times the price of a Technetium-99m scan, so each new label lifts revenue far faster than volume.

GE HealthCare's October 2026 agreement to buy Sofie Biosciences, with 21 cyclotrons across 15 U.S. sites, shows where isotope value is migrating: toward short-lived PET emitters made close to the patient. Technetium-99m is still the dominant isotope at 33.7% of 2025 value (USD 3,116.3 Mn); its six-hour half-life, generator-based supply and low cost keep it inside about 80% of nuclear medicine procedures worldwide. Fluorine-18 is the fastest-growing isotope, climbing from USD 940.2 Mn in 2023 to USD 1,245.6 Mn in 2025 at a 15.1% two-year CAGR, carried by PSMA, amyloid and the new Flyrcado cardiac PET tracers. Lutetium-177 follows at 14.0%, reflecting the Pluvicto and Lutathera ramp, while Actinium-225 is held back to 9.4% by isotope scarcity rather than demand.

Pluvicto's third U.S. label in July 2026 — for hormone-sensitive disease, based on the 1,144-patient PSMAddition trial — illustrates why cancer care dominates this category. Oncology holds 46.8% of 2025 revenue (USD 4,327.2 Mn), since PSMA-PET staging and Lutetium-177 therapy are paired around the same prostate and neuroendocrine patients and each patient generates both a diagnostic and a therapy spend. Neurology is the fastest-growing application, rising from USD 1,101.6 Mn in 2023 to USD 1,511.1 Mn in 2025 at a 17.1% two-year CAGR, as amyloid PET has become a gate for anti-amyloid Alzheimer's drugs and CMS dropped its restrictive coverage rule in 2023. Cardiology remains the second-largest application at 20.6%, and the arrival of F-18 cardiac PET gives it a new growth lever.

Novartis now delivers Pluvicto to nearly 600 U.S. treatment sites, typically within five days of an order, and nearly all of them sit inside hospital nuclear medicine departments. That explains why hospitals are the dominant end user at 53.2% of 2025 revenue (USD 4,924.1 Mn): radioligand therapy needs licensed shielded rooms, radiation safety officers and inpatient back-up that few outpatient settings have. Cancer treatment centers are the fastest-growing end user at a 12.4% two-year CAGR, rising to USD 990.3 Mn as dedicated theranostics units take on high-volume Lutetium-177 cycles. Diagnostic imaging centers hold 23.0% and grow at 11.8%, with operators such as RadNet reporting a 16.2% rise in same-center PET/CT volume in mid-2025.

Vectomat Insights counts the market in patient doses and estimates about 51.6 million doses were administered worldwide in 2025, consistent with the 50 million-plus nuclear medicine procedures performed each year. Diagnostic agents are the volume leader at roughly 98.0% of doses, yet therapeutic agents earn 43.0% of revenue from only about 2.0% of doses. That volume-value split implies an average of about USD 104 per diagnostic dose against roughly USD 3,850 per therapeutic dose, or about USD 179 blended.

This is a market where controlling the isotope matters as much as owning the molecule. Novartis remains the revenue leader on the strength of Pluvicto and Lutathera, but its moat is narrowing: Curium won FDA approval for a Lutathera equivalent in September 2026 and agreed to absorb Lantheus a month earlier. The competitive set splits into three tiers — isotope producers, branded agent developers and radiopharmacy networks — and the most aggressive players are integrating across them. Large pharma entrants such as Bristol Myers Squibb and Bayer are building or buying Actinium-225 supply rather than waiting on merchant producers. Key players include Novartis, Lantheus, Curium, GE HealthCare, Bayer, Telix Pharmaceuticals, Cardinal Health, Eckert & Ziegler, ITM Isotope Technologies Munich, NorthStar Medical Radioisotopes, Bristol Myers Squibb, Siemens Healthineers, SHINE Technologies, Jubilant Pharmova, SK Biopharmaceuticals, among others.

Three strategic themes run through the company table. First, vertical integration: RayzeBio, Cardinal Health and ITM all pair isotope production with drug or dose manufacturing. Second, consolidation, with two deals worth a combined USD 8.9 Bn announced between August and October 2026. Third, generic entry, as Bexlutry tests whether radioligand pricing can hold once 505(b)(2) equivalents reach the market.

Isotope Production and Generator Supply — Upstream, research reactors, cyclotrons and accelerators make the parent isotopes. About 95% of the world's Mo-99 still comes from six reactors, five of them over 50 years old, so a single outage ripples into hospitals within days. New capacity is arriving from accelerator and fusion-driven producers: SHINE can supply 100,000 Lutetium-177 doses a year and NorthStar's Actinium-225 file was accepted by the FDA in April 2026. Key players: Curium, Eckert & Ziegler, SHINE Technologies, NorthStar Medical Radioisotopes, ITM Isotope Technologies Munich.

Radiolabelling and Drug Manufacturing — Midstream, developers bind the isotope to a targeting molecule and release finished doses under GMP. Because Lutetium-177 decays with a half-life of about 6.7 days and Fluorine-18 in under two hours, plants must sit close to patients. That is why Novartis runs sites in New Jersey, Indiana, Spain and Italy, and why Bristol Myers Squibb is adding a second RayzeBio plant in Indiana. Key players: Novartis, Bayer, Bristol Myers Squibb, Telix Pharmaceuticals, Lantheus.

Radiopharmacy Distribution and Administration — Downstream, nuclear pharmacies compound and deliver unit doses, often on same-day schedules, to hospitals and imaging centres. Cardinal Health operates about 130 nuclear pharmacies and 30 PET cyclotron facilities in the U.S., while Siemens Healthineers' PETNET and Jubilant's 45 U.S. radiopharmacies cover much of the remaining PET and SPECT demand. Final administration needs licensed shielded rooms and trained staff. Key players: Cardinal Health, Siemens Healthineers, Jubilant Pharmova, GE HealthCare.

North America is the largest regional market at a 40.3% share, built on the world's densest network of PET scanners, radiopharmacies and radioligand treatment sites, while Asia Pacific is the fastest-growing region because Japan, South Korea and China are adding domestic isotope production and approving therapies years after the U.S. and Europe did.

Pluvicto can now be shipped to nearly 600 U.S. treatment sites, a delivery network no other region matches. North America holds 40.3% of the 2025 market, worth USD 3,727.2 Mn, and the United States accounts for USD 2,929.2 Mn of that, growing at a 9.4% CAGR to USD 7,193.2 Mn by 2035. CMS's decision to pay separately for diagnostic radiopharmaceuticals above USD 630 per day from January 2025 lifted the reimbursement ceiling on newer PET tracers, and Canada adds supply depth through Bruce Power's commercial Lutetium-177 production. The weak point is upstream: U.S. Technetium-99m supply fell by up to 40% during the October 2024 Petten outage. Bristol Myers Squibb's USD 173 Mn second RayzeBio plant in Whitestown, Indiana, announced in August 2026, is the region's clearest bet on domestic Actinium-225.

Construction of the Pallas research reactor formally began in the Netherlands in September 2025, backed by about EUR 2 Bn of state funding, to replace the HFR Petten unit that supplies roughly 30% of the world's medical isotopes. Europe holds 25.9% of the 2025 market (USD 2,395.4 Mn). Germany is the leading country at USD 680.8 Mn, expanding at a 9.0% CAGR to USD 1,611.7 Mn by 2035, and it is home to three isotope and therapy specialists — Eckert & Ziegler, ITM and Bayer. Access is the binding constraint: only 21% of eligible German mCRPC patients received PSMA-PET in 2025 data presented at ESMO, and France reached just 12%. Europe's position is therefore a supply-side asset base waiting on treatment-slot capacity, not a demand problem.

Japan approved Pluvicto, Locametz and the GalliaPharm generator together in September 2025, opening the region's second-largest market to full theranostic pairing. Asia Pacific holds 22.7% of 2025 revenue (USD 2,099.4 Mn) and is the fastest-growing region in this report. South Korea leads country-level growth at a 13.0% CAGR, rising from USD 280.9 Mn in 2025 to USD 953.5 Mn by 2035, helped by KIRAMS cyclotron Actinium-225 production approved in May 2025 and SK Biopharmaceuticals' December 2025 Ac-225 supply deal with Eckert & Ziegler. China's CNNC produced its first domestic Lutetium-177 in December 2024. India remains supply-constrained, with 19 of 52 Mo-99 batches short in 2024–25. Domestic isotope output, once Korea's Kijang reactor runs, should steadily lift the region's share through 2035.

Argentina's CNEA plans to commission the RA-10 multipurpose reactor in 2026, with full operation in 2027 and the aim of Mo-99 self-sufficiency plus exports. Latin America accounts for 4.9% of the 2025 market, or USD 453.2 Mn. Brazil leads the region: IPEN meets about 85% of national nuclear medicine demand across roughly 450 clinics, yet it still imports Mo-99 raw material from South Africa, Russia and the Netherlands. Brazil's own RMB reactor, an OPAL-based design costing about USD 500 Mn, targets completion in 2030. Until those reactors run, supply security caps regional growth, and the region's base-year share stands at 4.9%.

King Faisal Specialist Hospital & Research Centre in Riyadh runs three cyclotrons, produces more than 35 radiopharmaceuticals including Lutetium-177, and supplies over 30,000 patient doses a year to 20 Saudi cities. The Middle East holds 3.1% of 2025 revenue, worth USD 286.7 Mn. The GCC drives regional demand through hospital-led theranostics programmes, and Turkey adds manufacturing depth through Curium's acquisition of Monrol. Specialist staffing and imported therapy isotopes remain the main constraints. The UAE moved to close that gap when SHINE Technologies signed a long-term Ilumira Lutetium-177 distribution agreement with Modawina Medical.

South Africa's NECSA opened a tender in 2026 for a 20–30 MW multipurpose reactor to replace SAFARI-1, commissioned in 1965 and still one of the few global Mo-99 sources, with the new unit due online around 2032–33. Africa accounts for 3.1% of the 2025 market (USD 286.7 Mn), level with the Middle East. South Africa and Egypt lead: Egypt operates an INVAP-built radioisotope production facility at its ETRR-2 complex, supported by an IAEA technical cooperation project. Access beyond a handful of urban centres is the main restraint. Structurally, Africa matters to this market more as an isotope exporter than as a consumer.

Isotope supply security programme — The U.S. DOE Isotope Program supplied the first accelerator-produced Actinium-225 from Brookhaven and Los Alamos for a U.S. human clinical trial in mid-2025, while the NNSA Mo-99 Program funds domestic non-HEU Mo-99 through cost-shared agreements with producers such as SHINE. (U.S. DOE Isotope Program / NNSA Mo-99 Program)

Reimbursement and funding initiative — From January 2025, CMS pays separately under the hospital outpatient system for diagnostic radiopharmaceuticals whose per-day cost exceeds USD 630, a change SNMMI welcomed and one that applies to roughly 26 agents. (CMS CY2025 OPPS separate payment policy for diagnostic radiopharmaceuticals)

Public health and cancer-care action plan — The EU SAMIRA Action Plan, presented in February 2021 alongside Europe's Beating Cancer Plan, targets secure radioisotope supply, quality and safety, and innovation, including a European Radioisotope Valley Initiative. (EU SAMIRA Action Plan)

Research-reactor investment — Governments are funding replacement reactors to secure Mo-99 and therapy isotopes: the Netherlands' EUR 2 Bn Pallas reactor, South Korea's KRW 765 Bn Kijang research reactor, and Argentina's RA-10 all aim to reduce reliance on ageing units. (Pallas reactor (Netherlands) and Kijang Research Reactor (South Korea))

Activity since July 2026 has clustered around three moves — label expansion, consolidation and generic entry — with two acquisitions worth a combined USD 8.9 Bn announced in ten weeks.